文献速递血管炎

巨细胞动脉炎患者长期托珠单抗治疗期间及治疗后的结局

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis.
PubMed 文献 · RMD Open · 2023-01-01

该单中心回顾性分析纳入65例接受托珠单抗治疗的巨细胞动脉炎患者,平均随访3.1年。托珠单抗治疗18个月时Kaplan-Meier估计复发率为15.5%,停药后18个月为47.3%;治疗超过12个月者复发风险显著低于12个月及以内停药者,多变量校正HR为0.01(95%CI 0.00至0.28,p=0.005)。

要点

  • 托珠单抗治疗18个月时Kaplan-Meier估计复发率为15.5%。
  • 停药后18个月Kaplan-Meier估计复发率为47.3%。
  • 治疗超过12个月者复发风险低于12个月及以内停药者,校正HR 0.01(95%CI 0.00至0.28,p=0.005)。

核心结论

  • 长期托珠单抗治疗与大多数巨细胞动脉炎患者维持缓解相关;托珠单抗停药后18个月估计复发率为47.3%。

研究设计与样本

  • 单中心回顾性分析,纳入2010年至2022年接受托珠单抗治疗的巨细胞动脉炎患者65例,平均(SD)随访3.1(1.6)年。

主要发现

  • 初始托珠单抗疗程平均(SD)持续1.9(1.1)年;治疗18个月时Kaplan-Meier估计复发率为15.5%。
  • 45例(69.2%)因达到满意缓解而停用首个托珠单抗疗程,6例(9.2%)因不良事件停药;停药后18个月Kaplan-Meier估计复发率为47.3%。
  • 与治疗12个月及以内停用托珠单抗者相比,治疗超过12个月者复发的多变量校正HR为0.01(95%CI 0.00至0.28,p=0.005)。
  • 13例患者接受了超过1个托珠单抗疗程;汇总所有治疗期间与未治疗期间,多变量校正年化复发率(95%CI)分别为0.1(0.1至0.2)与0.4(0.3至0.7),p=0.0004。
  • 76.9%的患者停用泼尼松;研究期间11例(16.9%)患者发生13起严重不良事件。

关键数值与推荐

  • 复发定义为任何巨细胞动脉炎临床表现重新出现且需要加强治疗,不论C反应蛋白水平和红细胞沉降率如何。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess outcomes in giant cell arteritis (GCA) patients during and after long-term tocilizumab (TCZ) treatment. METHODS: Retrospective analysis of GCA patients treated with TCZ at a single centre (2010-2022). Time to relapse and annualised relapse rate during and after TCZ treatment, prednisone use, and safety were assessed. Relapse was defined as reappearance of any GCA clinical manifestation that required treatment intensification, regardless of C reactive protein levels and erythrocyte sedimentation rate. RESULTS: Sixty-five GCA patients were followed for a mean (SD) of 3.1 (1.6) years. The mean duration of the initial TCZ course was 1.9 (1.1) years. The Kaplan-Meier (KM)-estimated relapse rate at 18 months on TCZ was 15.5%. The first TCZ course was discontinued due to satisfactory remission achievement in 45 (69.2%) patients and adverse events in 6 (9.2%) patients. KM-estimated relapse rate at 18 months after TCZ discontinuation was 47.3%. Compared with patients stopping TCZ at or before 12 months of treatment, the multivariable adjusted HR (95% CI) for relapse in patients on TCZ beyond 12 months was 0.01 (0.00 to 0.28; p=0.005). Thirteen patients received >1 TCZ course. Multivariable adjusted annualised relapse rates (95% CI) in all periods on and off TCZ aggregated were 0.1 (0.1 to 0.2) and 0.4 (0.3 to 0.7), respectively (p=0.0004). Prednisone was discontinued in 76.9% of patients. During the study, 13 serious adverse events occurred in 11 (16.9%) patients. CONCLUSION: Long-term TCZ treatment was associated with remission maintenance in most patients with GCA. The estimated relapse rate by 18 months after TCZ discontinuation was 47.3%.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Matza MA, Dagincourt N, Mohan SV, et al. Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis. RMD Open. 2023. PMID: 37024237. doi:10.1136/rmdopen-2022-002923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。